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Abstract
Background:  Cockroach exposure is a major risk factor for the development of asthma.
Inhalation of fecal remnants (frass) is the likely sensitizing agent; however isolated frass has not been
tested for its ability to induce experimental asthma in mice.
Methods: Mice (Balb/c or C57Bl/6) were sensitized and challenged with GC frass or GC frass
devoid of proteases and measurements of airway inflammation and hyperresponsiveness were
performed (interleukin (IL)-5, -13, and interferon gamma (IFNγ) levels in bronchoalveolar lavage
fluid, serum IgE levels, airway hyperresponsiveness, cellular infiltration, and mucin production).
Results: Sensitization and challenge of Balb/c mice with GC frass resulted in increased airway
inflammation and hyperresponsiveness. C57Bl/6 mice were not susceptible to this model of
sensitization; however they were sensitized to GC frass using a more aggressive sensitization and
challenge protocol. In mice that were sensitized by inhalation, the active serine proteases in GC
frass played a role in airway hyperresponsiveness as these mice had less airway
hyperresponsiveness to acetylcholine and less mucin production. Proteases did not play a role in
mediating the allergic inflammation in mice sensitized via intraperitoneal injection.
Conclusion: While both strains of mice were able to induce experimental asthma following GC
frass sensitization and challenge, the active serine proteases in GC frass only play a role in airway
hyperresponsiveness in Balb/c mice that were susceptible to sensitization via inhalation. The
differences in the method of sensitization suggest genetic differences between strains of mice.
Introduction
The principal domestic cockroach species that commonly
infests homes in the United States are the German cock-
roaches (GC; Blattella germanica). During infestation,
cockroaches (CR) produce a variety of substances that
may be allergenic including exoskeleton, secretions, egg
castings and fecal remnants (frass). Of these, the whole
body CR and frass have been shown to contain significant
and similar allergenic activity [1], suggesting that most of
the allergenic activity is released in the frass. Although the
sensitization route of CR exposure is not fully understood,
it is likely that inhalation of frass is a main route of expo-
sure. Frass particles are very dry; therefore they may incor-
porate into house dust more readily than the hard
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chitinous materials. In fact, significant quantities of CR
antigen were found in household dust [2,3]. While frass
contains high levels of the cockroach allergens Bla g1 and
Bla g2 [4], it also contains active serine proteases [5,6],
coliforms [7], pheromones, and a number of proteins and
other components. While frass is the most likely source of
GC allergen exposure, isolated GC frass has never been
used as a sensitizing agent to induce the experimental
asthma phenotype in mice.
A number of studies have strongly suggested that cock-
roach allergens are a significant cause of asthma (for
review [8]) and that it may be more important relative to
exposure to other allergens. Indoor concentrations of CR
allergen, but not house dust mite, were found to be signif-
icantly associated with recurrent wheezing and asthma
[9]. For example, one study showed that in 63 children
less than 4 years of age, 24% were sensitized to cockroach
allergen [10]. In inner-city asthmatics which require fre-
quent emergency room and hospital visits, sensitization
to cockroach allergen is highly prevalent, suggesting the
likelihood that cockroach exposure may be responsible
for inducing their symptoms [11-14]. Early life cockroach
allergen exposure was shown to predict allergen-specific
responses by 2 years of age [15]. A correlation in the rise
of adolescent asthma in densely populated areas and
allergies to cockroach antigen have been shown [16,17].
While this increase cannot be solely linked to cockroach
exposure, roughly 60% of inner city children have highly
elevated IgE levels specific for cockroach [18]. Together
these studies have led investigators to speculate that cock-
roach allergens are important mediators of allergy and
asthma and therefore warrant their further study.
Much of the work in murine models of allergen-induced
allergic inflammation has been performed using ovalbu-
min (OVA) as a sensitizing agent. In order to elicit an
allergic response to OVA, mice must be immunized by
intraperitoneal injection of OVA bound to an adjuvant
such as aluminum hydroxide (alum). While allergen-
induced allergic inflammation is detected, these studies
do not mirror human susceptibility of this disease. There-
fore in this report we attempt to address not only the use
of GC frass as a sensitizing agent, but also to demonstrate
a model of allergic sensitization in mice that mirrors the
human etiology of allergic asthma. We will use two meth-
ods of sensitization to confirm the role of GC frass in
mediating allergen-induced allergic inflammation in
mice. The first method is sensitization and challenge by
intratracheal inhalation, and the second method is sensi-
tization by intraperitoneal injection with GC frass bound
to alum with an intratracheal challenge. In addition, since
GC frass contains active serine proteases [6] we will inves-
tigate the role of active proteases in regulating airway
inflammation and airway hyperresponsiveness.
Materials and methods
Cockroach frass
Fecal remnants (frass) were collected from German cock-
roaches (Blattella germanica) and reconstituted as previ-
ously described [5]. The frass preparation was frozen in
aliquots and used throughout the entire experiment. To
inhibit protease activity in frass, frass was pre-treated with
aprotinin (a specific inhibitor of serine proteases; 10 μg/
ml for 30 min at 37°C) prior to use. Protease activity was
determined using the Azocoll assay as previously
described [19]. GC frass was determined to contain 19 μg
protease activity/mg frass and aprotinin treatment inhib-
ited 80% of the protease activity [6] and will hence be
referred to as protease-free GC frass. Endotoxin levels were
determined by Limulus Amebocyte assay by Charles Riv-
ers Laboratories (Charleston, SC) to be 922.93 ng endo-
toxin/mg frass. Bla g2 levels were measured by ELISA
(Indoor Biotechnologies, Charlottesville, VA) according
to manufacturers' specifications and determined to be 5.3
μg/mg frass.
Animals
Six week old female Balb/c or C57Bl/6 mice were
obtained from Jackson Laboratory (Bar Harbor, ME) and
housed in a laminar hood in a virus-free animal facility.
These studies conformed to the principles for laboratory
animal research outlined by the Animal Welfare Act and
the Department of Health, Education, and Welfare
(National Institutes of Health). These studies were
approved by the Cincinnati Children's Hospital Medical
Center Institutional Animal Care and Use Committee.
Sensitization and challenge protocols
Murine strains are known to exhibit different immune
responses, with Balb/c mice being more responsive and
C57Bl/6 mice being less responsive to allergen challenge.
Therefore, we compared a sensitization by inhalation only
protocol to the standard sensitization by intraperitoneal
injection followed by inhalation challenge. In one
method, GC frass was delivered via intratracheal aspira-
tion challenge. Briefly, anesthetized mice (45 mg/kg keta-
mine and 8 mg/kg xylazine) were suspended on a 60
degree incline board. With the tongue gently extended, a
40 μl aliquot of PBS or GC frass is placed in the back of
the oral cavity and aspirated by the mouse [20]. Balb/c
mice were given three challenges of PBS (40 μl) or GC
frass (40 μg/40 μl) on days 0, 7, and 14 and harvested on
day 17 (Figure 1A). In some experiments, mice were also
treated with PBS pretreated with aprotinin (10 μg/ml) or
GC frass pretreated with aprotinin. In the other method,
mice were immunized with PBS or 10 μg/ml GC frass
bound to alum (Imject Alum; Pierce Biotechnology, Rock-
ford, IL) on day 0 and 7, followed by intratracheal inhala-
tion challenges with GC frass (40 μg/40 μl) on days 14
and 19. Mice were harvested on day 22 (Figure 1B). InRespiratory Research 2007, 8:91 http://respiratory-research.com/content/8/1/91
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some experiments, mice were sensitized and challenged
with aprotinin-treated PBS or GC frass.
Airway hyperresponsiveness measurements
Allergen-induced AHR was determined as we have previ-
ously described [21]. Briefly, mice were anesthetized 72
hours after the last GC frass exposure, intubated and ven-
tilated at a rate of 120 breaths per minute with a constant
tidal volume of air (0.2 ml), and paralyzed with decame-
thonium bromide (25 mg/kg). After establishment of a
stable airway pressure, 25 μg/kg weight of acetylcholine
was injected i.v. and dynamic airway pressure (airway
pressure time index [APTI] in cm-H2O × sec-1) was fol-
lowed for 5 minutes.
Assessment of airway inflammation
Lungs were lavaged thoroughly with 1 ml of Hanks bal-
anced salt solution without calcium or magnesium. The
lavage fluid was centrifuged (1,800 rpm for 10 min), the
supernatant was removed for cytokine analysis and imme-
diately stored at -80°C. Total cell numbers were counted
on a hemocytometer. Smears of BAL cells prepared with a
Cytospin II (Shandon Thermo, Waltham, MA) were
stained with Diff-Quick (Thermo Electron Corporation,
Pittsburg, PA) solution for differential cell counting.
Cytokine production
Liberase/DNase I digests of the lung were prepared to
obtain single lung cell suspensions. Single cell suspen-
sions (2.5 × 105) were incubated for 72 hours in culture
medium (RPMI) or in RPMI treated with Conconavalin A
Sensitization and challenge protocols Figure 1
Sensitization and challenge protocols. A. Protocol for Balb/c mice. B. Protocol for C57Bl/6 mice.Respiratory Research 2007, 8:91 http://respiratory-research.com/content/8/1/91
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(10 μg/ml) and supernatants were analyzed by ELISA for
TH2 cytokine (IL-5 and IL-13) or TH1 cytokine (inter-
feron (IFN) γ) expression as previously described [22].
Histology
Whole lungs were removed and formalin fixed. Lungs
were embedded in paraffin, sectioned, and stained with
haematoxylin and eosin (H&E) and Periodic Acid Schiff
(PAS). To quantify mucin production, we counted airways
and determined the percentage of mucin stained airways
(mean ± SEM; n= 3 slides per condition). Next, we picked
representative airways and counted total and mucin posi-
tive cells in that airway and determined the percentage of
mucin positive cells (mean ± SEM; n = 5 airways per con-
dition).
Statistical analysis
When applicable, statistical significance was assessed by
one-way analysis of variance (ANOVA). Differences iden-
tified by ANOVA were pinpointed by Student-Newman-
Keuls' multiple range test.
Results
GC frass induced airway inflammation and 
hyperresponsiveness in mice
Mice were sensitized and challenged mice with GC frass
via intratracheal inhalation as depicted in Figure 1A. Sen-
sitization and challenge with GC frass significantly
increased airway responsiveness to cholinergic agents in
Balb/c mice but not C57Bl6 mice (Figure 2A). Allergen
inhalation induced increases in the TH2 cytokines IL-5
and IL-13 in both strains of mice following allergen chal-
lenge (Figure 2B). In Balb/c mice, there was a decrease in
the TH1 cytokine IFNγ following allergen challenge (Fig-
ure 2B). Serum IgE levels were increased in Balb/c, but not
C57Bl6 mice following GC frass inhalation (Figure 2C).
Cellular infiltration into the BAL fluid of Balb/c mice
showed increased numbers of eosinophils, neutrophils,
macrophages and lymphocytes following sensitization
and challenge with GC frass (Table 1). Histological exam-
ination of the Balb/c mouse lung following GC frass treat-
ment showed dense perivascular and peribronchiolar
infiltrates (Figure 3 A+B) and abundant mucin in epithe-
lial cells (Figure 3 C+D) compared to PBS treatment. No
mucin was detected in PBS treated Balb/c mice, while 49
± 1% of the airways stained positive for mucin in mice
sensitized and challenged with GC frass. Of those stained
airways, 88 ± 3% of the cells in the airway were positive
for mucin. These data demonstrate that Balb/c mice are
susceptible to GC frass-induced allergic inflammation and
airway hyperresponsiveness following sensitization and
challenge by intratracheal inhalation, while C57Bl/6 mice
only had increases in TH2 cytokine levels, but no increase
in IgE or airway hyperresponsiveness. These data suggests
a genetic difference in susceptibility to inhaled allergen
between these mouse strains.
The role of active serine proteases in mediating airway 
inflammation and airway hyperresponsiveness in Balb/c 
mice
Balb/c mice were sensitized via intratracheal inhalation
with PBS, aprotinin-treated PBS, GC frass, or aprotinin-
treated GC frass (which we refer to as protease-free GC
frass). Inhalation of protease-free GC frass resulted in
reduced airway hyperresponsiveness to acetylcholine
compared to protease-containing GC frass (Figure 4A).
Removal of the serine proteases did not alter TH2 cytokine
production, IFNγ production (Figure 4B) or serum IgE lev-
els (Figure 4C). Aprotinin was used to inhibit serine pro-
tease activity in GC frass, which we show did not affect
cytokine production, airway hyperresponsiveness or lung
histology (data not shown). There was a small decrease in
the amount of perivascular and peribronchiolar infiltrates
in the mice challenged with aprotinin-treated GC frass
than compared to GC frass as determined by H&E staining
(data not shown). Notably, there was much less mucin
production in mice treated with aprotinin-treated frass
compared to protease containing GC frass (Figure 5 A+B).
Assessment of the airways showed that GC frass inhala-
tion resulted in positive mucin staining in 50% of the air-
ways compared to 25% in protease-free GC frass-treated
mice. Strikingly however, was the decreased amount of
mucin positive cells in each airway. GC frass had 88 ± 3%
mucin positive cells compared to only 22 ± 7% mucin
positive cells in protease-free GC frass treated mouse air-
ways (n = 5). Interestingly, the increase in BAL fluid eosi-
nophils, neutrophils, macrophages and lymphocytes was
unaffected by the inhibition of the serine proteases in
frass (Table 2). These data suggest that GC frass derived
proteases play a role in modulating airway hyperrespon-
siveness and mucin production, but are not required for
TH2 skewing and IgE production following GC frass treat-
ment.
GC frass induced airway inflammation and 
hyperresponsiveness in C57Bl/6 mice
Next we asked if GC frass was able to induce allergic
asthma in C57Bl/6 mice (Figure 1B). Using this protocol,
we were able to establish airway hyperresponsiveness to
acetylcholine (Figure 6A). An increase in TH2 cytokine
production and a decrease in TH1 cytokine production
were also detected, although only the increase in IL-5 was
statistically significant (Figure 6B). Serum IgE levels were
significantly increased (Figure 6C). GC frass treatment
also resulted in increased eosinophils, neutrophils, mac-
rophages, lymphocytes and epithelial cells in the BAL
fluid (Table 3). Histological examination of the lung fol-
lowing sensitization and challenge of GC frass compared
to PBS showed dense perivascular and peribronchiolarRespiratory Research 2007, 8:91 http://respiratory-research.com/content/8/1/91
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GC frass-induced experimental allergic asthma in Balb/c mice Figure 2
GC frass-induced experimental allergic asthma in Balb/c mice. Balb/c mice were challenged by intratracheal inhalation on day 0, 
7, and 14 with PBS (40 μl) or GC frass (40 μg/40 μl). On day 17, mice were anesthetized and acetylcholine was injected after 
establishment of a stable airway pressure. A. AHR was measured as airway pressure time index (APTI) in cm-H2O × sec -1 (* p 
< 0.001). B. Lungs from the mice were excised; cells dissociated and maintained in a single suspension culture for 3 days in the 
presence of Con A (10 μg/ml). Supernatants were removed and ELISAs were run for IL-5, IL-13 and IFNγ. These data are rep-
resented as cytokine (listed on the x-axis) in ng/ml from PBS or frass treated mice. C. Serum IgE levels were analyzed by ELISA 
(*p = 0.001). In all cases the data are expressed as mean ± SEM and represent 6–7 mice per group and statistical significance 
determined by ANOVA.
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infiltrates (Figure 7 A+B) and abundant mucin in epithe-
lial cells (Figure 7 C+D). 50 ± 2% of the GC frass chal-
lenged airways were positive for mucin staining,
compared to 8 ± 2% of the PBS challenged control mice.
These data demonstrate that while C57Bl/6 mice unable
to be sensitized to GC frass via intratracheal inhalation;
they were susceptible to aggressive sensitization and chal-
lenge with GC frass, suggesting a difference in the airways
between the C57Bl/6 and Balb/c mice.
Histological assessment of lung sections from PBS- or GC frass- exposed Balb/c mice Figure 3
Histological assessment of lung sections from PBS- or GC frass- exposed Balb/c mice. Haematoxylin and eosin (H&E) staining 
of sectioned lungs from PBS (A) and GC frass (B) treated Balb/c mice. Periodic Acid Schiff (PAS) staining of sectioned lungs 
from PBS (C) and GC frass (D) treated Balb/c mice. Representative slides are shown of sections from 6–7 mice per group.
Table 1: Differential cell count in BAL fluid of Balb/c mice
Mac Epi Eos Neut Lymph
PBS 3.1 ± 1.2 3.2 ± 1.0 0 0 0.3 ± 0.2
frass 10.5 ± 1.5 4.1 ± 1.0 1.2 ± 0.9 1.3 ± 0.3 2.7 ± 0.3
p value 0.005 0.54 0.008 0.005 0.001
Balb/c mice were challenged on day 0, 7, and 14 with PBS or GC frass (40 μg). On day 17, BAL fluid was harvested and differential cell counts 
performed. These data represent 7 mice per group and are expressed as mean ± SEM cell number ×104. Statistical significance between GC frass 
and PBS treatments were determined by ANOVA.Respiratory Research 2007, 8:91 http://respiratory-research.com/content/8/1/91
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GC frass serine proteases regulate airway inflammation and airway hyperresponsiveness in Balb/c mice Figure 4
GC frass serine proteases regulate airway inflammation and airway hyperresponsiveness in Balb/c mice. Balb/c mice were chal-
lenged on day 0, 7, and 14 with PBS, PBS pretreated with aprotinin (10 μg/ml), GC frass (40 μg) or GC frass pretreated with 
aprotinin. On day 17, mice were anesthetized and acetylcholine was injected after establishment of a stable airway pressure. A. 
AHR was measured as airway pressure time index (APTI) in cm-H2O × sec -1 (* p < 0.001). B. Lungs from the mice were 
excised, and cells dissociated and maintained in a single suspension culture for 3 days in the presence of Con A (10 μg/ml). 
Supernatants were removed and ELISAs were run for IL-5, IL-13 and IFNγ. These data are represented as cytokine (listed on 
the x-axis) in ng/ml from PBS or frass treated mice. C. Serum IgE levels were analyzed by ELISA (*p < 0.001). In all cases the 
data are expressed as mean ± SEM and represent 13–14 mice per group and statistical significance determined by ANOVA.
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Active serine proteases do not mediate airway 
inflammation and airway hyperresponsiveness in C57Bl/6 
mice
Using the same sensitization and challenge protocol for
C57Bl/6 mice (Figure 1B), we investigated the role of GC
frass associated proteases by using GC frass pretreated
with aprotinin. There was no effect of removal of GC frass
proteases on airway hyperresponsiveness to acetylcholine,
TH2 cytokine production, or serum IgE levels (data not
shown). There was a significant inhibition of IFNγ pro-
duction by removing the proteases from GC frass (data
not shown). In addition, there was no significant differ-
ence between PBS bound to alum and aprotinin-treated
PBS bound to alum for TH2 cytokine production, or
serum IgE levels (data not shown). There was an increase
in airway hyperresponsiveness to acetylcholine in the
aprotinin-treated PBS compared to PBS bound to alum,
but this increase was not statistically significant. These
data demonstrate that GC frass-derived proteases elicit a
direct effect on the airways to augment allergen-induced
airway inflammation and hyperresponsiveness.
Discussion
Using a method which reflects the natural exposure to
environmental allergens, inhalation of GC frass induced
allergic asthma as determined by increased TH2 cytokines
in the BAL fluid, increased serum IgE levels, increased
responsiveness to acetylcholine challenge, increased cellu-
lar infiltration into the airways and increased mucin pro-
duction in Balb/c mice. The same inhalation protocol
resulted in increased TH2 cytokines in C57Bl/6 mice, with
the other parameters not being affected. C57Bl/6 mice
were susceptible to sensitization and challenge with GC
frass; however this required an aggressive sensitization
and challenge protocol. The difference in allergen chal-
lenge suggests an inherent difference in the airways
between these mice. In the Balb/c mice, which were sus-
ceptible to sensitization via intratracheal inhalation, we
Histological assessment of lung sections from Balb/c mice exposed to GC frass or protease-depleted GC frass Figure 5
Histological assessment of lung sections from Balb/c mice exposed to GC frass or protease-depleted GC frass. Periodic Acid 
Schiff (PAS) staining of sectioned lungs from GC frass (A) and aprotinin-treated GC frass (D) treated Balb/c mice. Representa-
tive slides are shown of sections from 8 mice per group.
Table 2: Differential cell count in BAL fluid of Balb/c mice treated with GC frass or protease-depleted frass
Mac Epi Eos Neut Lymph
PBS 0.3 ± 0.08 0.5 ± 0.08 0 0.01 ± 0.003 0.005 ± 0.002
PBS-Ap 0.3 ± 0.09 0.3 ± 0.06 0 0.01 ± 0.002 0.005 ± 0.002
frass 1.9 ± 0.3 0.6 ± 0.1 0.4 ± 0.07 0.5 ± 0.09 0.58 ± 0.05
frass-Ap 1.6 ± 0.2 0.9 ± 0.3 0.5 ± 0.1 0.4 ± 0.08 0.7 ± 0.02
Balb/c mice were challenged on day 0, 7, and 14 with PBS, aprotinin-treated PBS (PBS-Ap), GC frass (40 μg/40 μl) or aprotinin-treated GC frass 
(frass-Ap). On day 17, BAL fluid was harvested and differential cell counts performed. These data represent 6 mice per group and are expressed as 
mean ± SEM cell number ×104. There were no statistical differences between PBS-Ap and PBS, nor were there differences between GC frass-Ap 
and GC frass. Statistical significance between GC frass and PBS treatments were determined by ANOVA (mac p < 0.001; eos p = 0.002; neut p < 
0.001; lymph p < 0.001).Respiratory Research 2007, 8:91 http://respiratory-research.com/content/8/1/91
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GC frass-induced experimental allergic asthma in C57Bl/6 mice Figure 6
GC frass-induced experimental allergic asthma in C57Bl/6 mice. C57Bl/6 mice were sensitized on day 0 and 7 with an intraperi-
toneal injection of 100 ug/ml PBS or GC frass with alum. On days 14 and 19, an intratracheal inhalation was performed using 
PBS (40 μl) or GC frass (40 μg/40 ml). On day 22, mice were anesthetized acetylcholine was injected after establishment of a 
stable airway pressure. A. AHR was measured as airway pressure time index (APTI) in cm-H2O × sec -1 (* p = 0.016). B. Lungs 
from the mice were excised, and cells dissociated and maintained in a single suspension culture for 3 days in the presence of 
Con A (10 μg/ml). Supernatants were removed and ELISAs were run for IL-5, IL-13 and IFNγ. These data are represented as 
cytokine (listed on the x-axis) in ng/ml from PBS or GC frass treated mice (*p = 0.012). C. Serum IgE levels were analyzed by 
ELISA (*p < 0.001). In all cases the data are expressed as mean ± SEM and represent 6–7 mice per group and statistical signifi-
cance determined by ANOVA.
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found that active serine proteases in GC frass played a role
in regulating airway hyperresponsiveness to acetylcholine
and mucin production. Removal of proteases from GC
frass had no effect on the C57Bl/6 mice which required
sensitization via intraperitoneal injection. Together these
data show that in mice susceptible to sensitization by
inhalation, GC frass related proteases play a role in aug-
menting the allergic asthma phenotype and suggests func-
tional differences in the airways of the strains of mice
tested in this study.
Histological assessment of lung sections from PBS or GC frass exposed C57Bl/6 mice Figure 7
Histological assessment of lung sections from PBS or GC frass exposed C57Bl/6 mice. Haematoxylin and eosin (H&E) staining 
of sectioned lungs from PBS (A) and GC frass (B) treated C57Bl/6 mice. Periodic Acid Schiff (PAS) staining of sectioned lungs 
from PBS (C) and GC frass (D) treated C57Bl/6 mice. Representative slides are shown of sections from 6–7 mice per group.
Table 3: Differential cell count in BAL fluid of C57Bl/6 mice
Mac Epi Eos Neut Lymph
PBS/alum 0.9 ± 0.07 0.9 ± 0.07 0 0.01 ± 0.003 0.02 ± 0.008
frass/alum 33.2 ± 2.1 6.8 ± 1.7 25.1 ± 6.1 8.1 ± 1.7 18.3 ± 3.7
p value <0.001 0.019 0.008 0.004 0.003
C57Bl/6 mice were given intraperitoneal injections of PBS with alum (PBS/alum) or GC frass with alum (frass/alum) on day 0 and 7. Intratracheal 
inhalations of PBS or GC frass were performed on days 14 and 19. On day 22, BAL fluid was harvested and differential cell counts performed. These 
data represent 7 mice per group and are expressed as mean ± SEM cell number ×104. Statistical significance between GC frass and PBS treatments 
were determined by ANOVA.Respiratory Research 2007, 8:91 http://respiratory-research.com/content/8/1/91
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While both mouse strains were able to induce allergic
experimental asthma following sensitization and chal-
lenge with GC frass, the mice differed in their susceptibil-
ity to GC frass. C57Bl/6 mice have a tendency towards
TH1 and consistently produce high levels of IFNγ [23].
Balb/c mice on the other hand, show a tendency towards
TH2 cytokine expression. This could be one explanation
why C57Bl/6 mice were unable to be sensitized via inha-
lation challenge, and the use of the adjuvant alum, which
promotes a TH2 response, was required. Consequently,
we noted differences in magnitude of TH2 cytokine levels
between the mice, with Balb/c mice having higher levels
both at baseline and following stimulation. However,
using the more aggressive sensitization and challenge pro-
tocols for the C57Bl/6 mice, similar increases in airway
responsiveness to acetylcholine, serum IgE levels, and
mucin production were detected. It is important to note
that while allergic asthma could be induced in C57Bl/6
mice, it was not by a natural exposure to GC frass.
Together these data suggest that functional differences in
the airways of Balb/c and C57Bl/6 mice could lead to dif-
ferences in airway susceptibility to allergen exposure.
The airway epithelium is the first contact between the lung
and aeroallergens, viruses and irritants, and as such, the
airway epithelium needs to respond appropriately. In
response to these stimuli, airway epithelial cells produce
inflammatory chemokines. That the airway epithelium
can respond to allergen treatment has been shown in a
number of studies. The house dust mite cysteine protease
Der p 1 caused disruption of intracellular tight junctions,
detachment of lung epithelial cells, and epithelial release
of cytokines in vitro [24,25]. We have previously reported
that GC frass contains active serine proteases which mod-
ulate cytokine expression via the activation of protease
activated receptor (PAR)-2 in human bronchial epithelial
cells in vitro [26]. PARs are a family of transmembrane
spanning receptors that are activated upon cleavage by a
variety of extracellular proteases. The role of PAR-2 in
allergic respiratory disease has been documented but is
still controversial. Since many of the allergens have been
shown to contain active proteases, this may be a mecha-
nism by which an allergen regulates the airway epithe-
lium.
Other studies have investigated the role of proteases in
modulating the experimental asthma phenotype in mice.
In the highly responsive A/J mouse strain, proteolytic
activity in the house dust mite allergen Der p 1 was shown
to induce sensitization toward IgE responses by a cysteine
protease-dependent mechanism [27]. Der p 1 has also
been shown to induce cellular infiltration into the lungs
in a protease-dependent manner in Balb/c mice [28].
Interestingly, both of the abovementioned models immu-
nized mice with allergen bound to alum by intraperito-
neal injection. Further work will shed additional light on
the role of aeroallergen-derived proteases in the develop-
ment of experimental asthma phenotype in mice.
A crucial step in mediating a T cell immune response is the
uptake, processing and presentation of antigen by antigen
presenting cells. It is possible that genetic differences in
airway epithelial cells between the murine strains could
lead to differences in allergen uptake and processing. The
epithelium produces a number of chemokines which reg-
ulate cellular recruitment, and as such the epithelium
could alter the immune response to allergens. Differences
in airway epithelial biology could dampen the damaging
effects of proteases inherent in allergens, or from the
release of oxygen radicals, proteases and soluble media-
tors of inflammation from neutrophils. This could be
accomplished by the synthesis of variable levels of endog-
enously expressed proteins such as alpha-1 antitrypsin or
secretory leukoprotease inhibitor, both of which protect
tissue against the destructive action of neutrophil elastase
at the site of inflammation. Our data suggests that the air-
way epithelium plays an important role in the sensitiza-
tion of mice to allergen, as exemplified by the different
susceptibility of the Balb/c and C57Bl/6 mouse strains to
induce experimental asthma.
In susceptible humans and animals, allergens induce TH2
driven production of IgE, airways hyperresponsiveness
and peribronchial inflammation. But the question
remains, what makes some humans susceptible? Our data
show that lung susceptibility to allergen is different from
other routes of sensitization, i.e. active proteases play an
important role in the sensitization process in the inhala-
tion model used for Balb/c mice. Sensitization via intra-
peritoneal injection of allergen with adjuvant also induces
experimental asthma, but in a fashion independent of
active proteases. The sensitization protocol for Balb/c
mice mimics the natural route of allergen sensitization,
i.e. inhalation of the allergen. In the allergen inhalation
model of asthma we present, allergen-derived proteases
play an important role in mediating allergic susceptibility.
It will be of considerable interest to determine the role of
active proteases in modulating human asthma.
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